CME Presentations

von Willebrand Disease Management


Presentations


Speakers

  • David Lillicrap, MD, FRCPC

    David Lillicrap, MD, FRCPC

    David Lillicrap, MD, FRCPC

    Professor

    David Lillicrap, MD, FRCPC, is a professor in the Department of Pathology and Molecular Medicine at Queen’s University in Kingston, Canada. His research interests are centered on molecular aspects of the hemostatic system, with a particular emphasis on the potential of molecular genetics and molecular biology to address questions relating to pathological hemostasis. Dr Lillicrap is a member of the World Federation of Hemophilia’s (WFH) Medical Advisory Board and a past chair of the WFH’s Research Committee. He is a past chairman of the International Society on Thrombosis and Haemostasis’ (ISTH) Scientific and Standardization Committee and is a current member of the Council of ISTH. Dr Lillicrap is currently co-editor-in-chief of the Journal of Thrombosis and Haemostasis.
  • Robert Sidonio, Jr, MD, MSc

    Robert Sidonio, Jr, MD, MSc

    Robert Sidonio, Jr, MD, MSc

    Associate Professor of Pediatrics

    Robert Sidonio, Jr, MD, MSc, is the associate director of Hemostasis and Thrombosis at Emory University in Atlanta, Georgia. His clinical and research interest is in investigating the bleeding phenotype and genotype of women with hemophilia carriage and low VWF funded by the Hemophilia of Georgia Clinical Scientist Development Grant. Dr Sidonio is the co-creator of the Atlanta Protocol, which combines Emicizumab and FVIII for immune tolerance induction. He is the principal investigator for the Emicizumab PUP and Nuwiq ITI trial, MOTIVATE study, ATHN 9 study (severe VWD), and Wilate prophylaxis (Wil-31) trial. Dr Sidonio received his medical degree from University of Alabama at Birmingham School of Medicine and completed his pediatric residency at the University of Louisville in Kentucky.

CME Information

von Willebrand Disease Management for Hematologists and Referring Clinicians: Diagnosis, Treatment, and Emerging Strategies


PIM Logo PQH Logo

LEARNING OBJECTIVES

After completing this activity, the participant should be better able to:
  • Distinguish VWD among varied clinical presentations and laboratory assays to improve timely diagnosis
  • Evaluate current treatment approaches for VWD
  • Review the rationale for and key components of anticipated consensus evidence-based guidelines
  • Assess the potential impact of prophylaxis on quality of life among patients with VWD
  • Summarize current and emerging prophylactic agents for patients with VWD
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the National Organization for Rare Disorders (NORD) and the Hemophilia Federation of America (HFA).

ACKNOWLEDGEMENT

Supported by an educational grant from Takeda Pharmaceuticals U.S.A, Inc.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION

Live Activity

Thursday, January 14, 2021 from 3:00pm – 4:00pm ET

Enduring Material

The enduring material will be available from January 14, 2021 to January 14, 2022.

TARGET AUDIENCE

The intended audience for this activity are hematologists, primary care providers, pediatricians, obstetricians, gynecologists, family physicians, internists, physician assistants, nurse practitioners, and other HCPs involved in the management of patients with von Willebrand disease.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com or www.ClinicalSeriesLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
David Lillicrap, MD
Professor
Queen’s University
Consulting Fees (e.g., advisory boards): Bayer, Biomarin, CSL, Sanofi, Takeda
Contracted Research: Biomarin, CSL, Octapharma, Sanofi
Robert F. Sidionio, Jr., MD, MSc
Associate Professor of Pediatrics
Children’s Healthcare of Atlanta
Emory University
Aflac Cancer and Blood Disorders
Consulting Fees (e.g., advisory boards): Bayer, Biomarin, Catalyst, Emergent, Hema Biologics, Novo Nordisk, Sanofi
Contracted Research: Genentech and Octapharma (Emi PUPs and Nuwiq ITI), Octapharma (MOTIVATE Study), Takeda (ATHN 9 study)

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Jaimee Harris-Gold, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com or ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.